Navigation Links
Cempra Pharmaceuticals Names Carl Foster Executive Vice President of Business Development
Date:1/5/2011

CHAPEL HILL, N.C., Jan. 5, 2011 /PRNewswire/ -- Cempra Pharmaceuticals announced that Carl Foster has been named Executive Vice President of Business Development.  Mr. Foster will be focusing on business development activities related to the company's two lead antibiotic programs, the next-generation fluoroketolide solithromycin (CEM-101), that is in Phase 2 clinical development for community-acquired bacterial pneumonia (CABP), and TAKSTATM (CEM-102 or fusidic acid), that has completed Phase 2 clinical trials for acute bacterial skin and skin structure infections (aBSSSI) including those caused by methicillin-resistant Staphylococcus aureus (MRSA).

Mr. Foster brings with him over 20 years of industry experience in business development and leadership in the biotechnology, pharmaceutical and diagnostic industries. Most recently, Mr. Foster was the Chief Executive Officer of Juilab, a European-based genomics company. Additionally, he held business development positions at several other development-stage biopharmaceutical companies including King Pharmaceuticals, Praecis Pharmaceuticals, Oxford GlycoSciences and Astra Merck.  Mr. Foster has also served as an advisor to pharmaceutical and biotechnology companies as a consultant and as a Managing Director with Ferghana Partners, Inc., an international investment banking group in New York City.

"Mr. Foster has a proven track record of success in business development," said Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra Pharmaceuticals. "He has extensive experience leading successful pharmaceutical development efforts to help companies maximize their portfolio's potential and capitalize on growth opportunities. His contribution will be vital because of the mid-clinical-stage status of our programs for solithromycin and TAKSTA."

Mr. Foster added, "Cempra's two lead antibiotic candidates not only have a significant commercial potential but also may help fulfill the need for new and effective antibiotics. Solithromycin and TAKSTA have the potential to treat CABP and aBSSSI, respectively. I am excited about the products we have to offer and I look forward to helping Cempra bring these two products to market."  

About Cempra PharmaceuticalsFounded in 2006, Cempra Pharmaceuticals is a privately-held, clinical-stage pharmaceutical company focused on developing antibacterials to address critical medical needs. Two lead products, both in late-stage clinical trials, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra is well-funded and is committed to developing commercially and medically differentiated and novel products that reduce development risk and provide a high financial return. The company is also utilizing its proprietary compound library and chemistry technology to develop novel macrolides without antibacterial activity for non-antibiotic uses such as COPD, chronic inflammatory and GI disorders. Additional information about Cempra can be found at www.cempra.com.Media Contacts:Russo Partners, LLCRobert E. Flamm, Ph.D.(212) 845-4226 Robert.flamm@russopartnersllc.com Tony Russo, Ph.D.(212) 845-4251Tony.russo@russopartnersllc.com
'/>"/>

SOURCE Cempra Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cempra Pharmaceuticals Names Richard Kent, M.D., to Its Board of Directors
2. Cempra Pharmaceuticals to Present at the UBS Global Life Sciences Conference
3. Cempra Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
4. Cempra Pharmaceuticals To Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17th
5. Presentations of Cempra Pharmaceuticals CEM-102 (fusidic acid) at the Infectious Diseases Society of America Annual Meeting Highlight Properties That Make It an Excellent Anti-MRSA Candidate
6. Data Presented on Cempra Pharmaceuticals CEM-101 at the Infectious Diseases Society of America Annual Meeting Reinforces Potency and Coverage Against Multidrug-Resistant S. Pneumoniae Isolates
7. Jazz Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference in San Francisco on January 12
8. MAP Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
9. Lexicon Pharmaceuticals to Present at the 29th Annual JPMorgan Healthcare Conference
10. Anadys Pharmaceuticals Initiates Phase IIb Study of ANA598 in HCV Patients
11. Optimer Pharmaceuticals Receives Orphan Drug Designation for Fidaxomicin for the Treatment of Pediatric Clostridium difficile Infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/5/2017)... 2017 The Cincinnati location ... Inc. (NYSE: DPLO), has been awarded a Top Workplaces ... Results are based on an employee survey administered by ... workplace improvement. The survey measures several aspects of workplace culture, ... ...
(Date:6/3/2017)... -- Eli Lilly and Company (NYSE: LLY ... 3 MONARCH 2 study showed that abemaciclib, a ... with fulvestrant, significantly improved progression-free survival (PFS) compared ... hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative ... progressed after endocrine therapy (median PFS, 16.4 vs. ...
(Date:6/1/2017)... , June 1, 2017 Nutriceutical Holdings (NH), ... Recommended Solutions (VRS), and KD Pharma Group have decided ... Holdings by KD Pharma Group. KD Pharma Group will ... option to acquire the entire company. "We ... They are committed to growing the NH companies by ...
Breaking Medicine Technology:
(Date:6/23/2017)... MA (PRWEB) , ... June 23, 2017 , ... ... Care Reconciliation Act (BCRA), their proposed healthcare bill to repeal and replace the ... May, the Senate bill would make significant cuts to Medicaid, a public health ...
(Date:6/23/2017)... ... June 23, 2017 , ... Everybody has their own personal preference when ... read it, and some people don't like it at all. FindaTopDoc took a look ... , Erotic literature can give readers a taste of their deepest, darkest fantasies and ...
(Date:6/23/2017)... ... June 23, 2017 , ... 21 Middle East and South Asia Leaders Selected ... from government, business and civil society in 11 countries across the Middle East and ... in a transformative exchange of knowledge and ideas with the leading minds in their ...
(Date:6/23/2017)... ... June 23, 2017 , ... Ulster University, Magee Campus in Northern Ireland is ... 3 pm to present to graduate students exciting new and innovative hope research based ... led by The Health Improvement Service of the Western Health & Social Care Trust ...
(Date:6/23/2017)... ... June 23, 2017 , ... Moore Insurance, an eastern Texas ... to asset protection and financial planning services, is teaming up with the For ... of children with cancer and other chronic diseases. , The For A Day ...
Breaking Medicine News(10 mins):